These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 38902532

  • 1. Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.
    Roa P, Foglizzo V, Harada G, Repetto M, Kulick A, de Stanchina E, de Marchena M, Auwardt S, Sayed Ahmed S, Bremer NV, Yang SR, Feng Y, Zhou C, Kong N, Liang R, Xu H, Zhang B, Bardelli A, Toska E, Ventura A, Drilon A, Cocco E.
    Br J Cancer; 2024 Aug; 131(3):601-610. PubMed ID: 38902532
    [Abstract] [Full Text] [Related]

  • 2. NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors.
    Kim EE, Park CK, Kim SK, Phi JH, Paek SH, Choi JY, Kang HJ, Lee JH, Won JK, Yun H, Park SH.
    Acta Neuropathol Commun; 2024 Jul 16; 12(1):118. PubMed ID: 39014476
    [Abstract] [Full Text] [Related]

  • 3. NTRK fusion-positive cancers and TRK inhibitor therapy.
    Cocco E, Scaltriti M, Drilon A.
    Nat Rev Clin Oncol; 2018 Dec 16; 15(12):731-747. PubMed ID: 30333516
    [Abstract] [Full Text] [Related]

  • 4. Testing algorithm for identification of patients with TRK fusion cancer.
    Penault-Llorca F, Rudzinski ER, Sepulveda AR.
    J Clin Pathol; 2019 Jul 16; 72(7):460-467. PubMed ID: 31072837
    [Abstract] [Full Text] [Related]

  • 5. Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer.
    Liu Z, Yu P, Dong L, Wang W, Duan S, Wang B, Gong X, Ye L, Wang H, Tian J.
    J Med Chem; 2021 Jul 22; 64(14):10286-10296. PubMed ID: 34253025
    [Abstract] [Full Text] [Related]

  • 6. Pyrazolo[1,5-a]pyrimidine as a Prominent Framework for Tropomyosin Receptor Kinase (Trk) Inhibitors-Synthetic Strategies and SAR Insights.
    Mahajan AT, Shivani, Datusalia AK, Coluccini C, Coghi P, Chaudhary S.
    Molecules; 2024 Jul 29; 29(15):. PubMed ID: 39124968
    [Abstract] [Full Text] [Related]

  • 7. Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations.
    Murray BW, Rogers E, Zhai D, Deng W, Chen X, Sprengeler PA, Zhang X, Graber A, Reich SH, Stopatschinskaja S, Solomon B, Besse B, Drilon A.
    Mol Cancer Ther; 2021 Dec 29; 20(12):2446-2456. PubMed ID: 34625502
    [Abstract] [Full Text] [Related]

  • 8. Evolving role of entrectinib in treatment of NTRK-positive tumors.
    Chawla N, Bui NQ, Seetharam M.
    Future Oncol; 2021 Aug 29; 17(22):2835-2846. PubMed ID: 33896226
    [Abstract] [Full Text] [Related]

  • 9. Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
    Farago AF, Demetri GD.
    Future Oncol; 2020 Mar 29; 16(9):417-425. PubMed ID: 32129093
    [Abstract] [Full Text] [Related]

  • 10. Tropomyosin receptor kinase inhibitors: an updated patent review for 2016-2019.
    Bailey JJ, Jaworski C, Tung D, Wängler C, Wängler B, Schirrmacher R.
    Expert Opin Ther Pat; 2020 May 29; 30(5):325-339. PubMed ID: 32129124
    [Abstract] [Full Text] [Related]

  • 11. TRK inhibitors in TRK fusion-positive cancers.
    Drilon A.
    Ann Oncol; 2019 Nov 01; 30(Suppl_8):viii23-viii30. PubMed ID: 31738426
    [Abstract] [Full Text] [Related]

  • 12. TRK inhibitors in TRK fusion-positive cancers.
    Drilon A.
    Ann Oncol; 2019 Nov 01; 30 Suppl 8():viii23-viii30. PubMed ID: 32223935
    [Abstract] [Full Text] [Related]

  • 13. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
    Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD, trial investigators.
    Lancet Oncol; 2020 Feb 01; 21(2):271-282. PubMed ID: 31838007
    [Abstract] [Full Text] [Related]

  • 14. A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib.
    Caldwell KJ, De La Cuesta E, Morin C, Pappo A, Helmig S.
    Pediatr Blood Cancer; 2020 Sep 01; 67(9):e28330. PubMed ID: 32452122
    [Abstract] [Full Text] [Related]

  • 15. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM, Nagasubramanian R, Davis JL, Rudzinski E, Feraco AM, Tuch BB, Ebata KT, Reynolds M, Smith S, Cruickshank S, Cox MC, Pappo AS, Hawkins DS.
    Lancet Oncol; 2018 May 01; 19(5):705-714. PubMed ID: 29606586
    [Abstract] [Full Text] [Related]

  • 16. NTRK fusions in lung cancer: From biology to therapy.
    Harada G, Santini FC, Wilhelm C, Drilon A.
    Lung Cancer; 2021 Nov 01; 161():108-113. PubMed ID: 34563714
    [Abstract] [Full Text] [Related]

  • 17. Larotrectinib in NTRK-Rearranged Solid TumorsPublished as part of the Biochemistry series "Biochemistry to Bedside".
    Wilson FH, Herbst RS.
    Biochemistry; 2019 Mar 26; 58(12):1555-1557. PubMed ID: 30865435
    [No Abstract] [Full Text] [Related]

  • 18. TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults.
    Harada G, Drilon A.
    Cancer Genet; 2022 Jun 26; 264-265():33-39. PubMed ID: 35334340
    [Abstract] [Full Text] [Related]

  • 19. Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinib.
    Rudzinski ER, Hechtman J, Roy-Chowdhuri S, Rudolph M, Lockwood CM, Silvertown J, Wierzbinska J, Shen K, Norenberg R, Nogai H, Hong DS, Drilon A, Laetsch TW.
    Cancer Genet; 2022 Jan 26; 260-261():46-52. PubMed ID: 34929613
    [Abstract] [Full Text] [Related]

  • 20. Loxo TRK inhibitor data wows oncologists.
    Dolgin E.
    Nat Biotechnol; 2017 Aug 08; 35(8):694-695. PubMed ID: 28787403
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.